Colchicine treatment of liver fibrosis.

摘要: Background/Aims: Because of its antifibrotic and anti-inflammatory effects, colchicine has been proposed as a treatment for liver disease. The results from clinical trials have however inconsistent. aim the present study was to evaluate effect in patients with hepatic fibrosis various etiologies. Methodology: Thirty-eight were randomized receive either 1mg per day (n=21, group A) or no agent (n=17, B). Treatment lasted at least 12 months. Liver biopsy performed prior entry after function tests, serum aminoterminal peptide procollagen III (PIIINP) levels CD4:CD8 ratio peripheral blood T lymphocytes (PBTLs) baseline bimonthly every 4 months post-treatment. Results: Mean albumin increased post-treatment period only A (p<0.05). PIIINP did not change significantly A; 7 reduction mean noticed during 24-month follow-up At baseline, correlation between focal bridging necrosis PBTLs (p<0.05) associated abrogation this correlation; comparison two groups revealed histological findings according Knodell criteria both remained unchanged follow-up. well tolerated all patients. Conclusions: Long-term appears exert an anti-inflammatory, anti-fibrotic immunomodulatory effect.